A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
about
Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines.Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma.
P2860
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
A phase-I study of lapatinib i ...... tive metastatic breast cancer.
@ast
A phase-I study of lapatinib i ...... tive metastatic breast cancer.
@en
type
label
A phase-I study of lapatinib i ...... tive metastatic breast cancer.
@ast
A phase-I study of lapatinib i ...... tive metastatic breast cancer.
@en
prefLabel
A phase-I study of lapatinib i ...... tive metastatic breast cancer.
@ast
A phase-I study of lapatinib i ...... tive metastatic breast cancer.
@en
P2093
P2860
P1476
A phase-I study of lapatinib i ...... itive metastatic breast cancer
@en
P2093
Caroline Lohrisch
Catalin Mihalcioiu
Elizabeth Eisenhauer
Karen Gelmon
Linda Hagerman
Mihaela Mates
Penelope Bradbury
Rachel Goodwin
Sara Taylor
Shingo Sakashita
P2860
P2888
P356
10.1186/S13058-017-0836-3
P577
2017-05-02T00:00:00Z
P6179
1084956239